Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Therapeutic Effects of Deferoxamine and Silymarin Versus Deferoxamine Alone in Β-Thalassemia Major Based on Findings of Liver Mri



Adibi A1 ; Shayganfar A1 ; Moayedi BS2 ; Gharagozloo M2 ; Maraashi SMJ1 ; Maracy M3 ; Adibi N4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Iran
  4. 4. Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Research in Medical Sciences Published:2012

Abstract

BACKGROUND: Thalassemia is an inherited disorder in which repeated blood transfusion is needed. This causes accumulation of iron in various organs. Silymarin is a natural medicinal plant that has been used for centuries in the treatment of liver depositions. In this study, magnetic resonance imaging (MRI) of liver, which has high accuracy in measuring liver iron concentration (LIC), was used to evaluate the effects of silymarin (Legalon) as an iron-chelating agent. METHODS: In this double-blind randomized clinicaltrial study, 48 thalassemic patients were enrolled during a period of 6 months. In order to evaluate the efficacy of Legalon on LIC, the control group was treated with deferoxamine and placebo tablets while the case group received a combination of deferoxamine and silymarin. MRI was performed for all patients before and after the intervention to determine liver iron using Gandon's protocol. RESULTS: Overall, 37 patients, including 22 controls and 15 cases, completed the study. The mean concentrations of liver iron at baseline were 290 ± 62 μmol/g and 328 ± 27.8 μmol/g in the control and case groups, respectively. The mean liver iron concentrations after 6 months of intervention were 290.4 ± 65.4 μmol/g and 334.6 ± 27.9 μmol/g in the control and case groups, respectively. No group experienced a significant difference in LIC change before and after the 6-month trial (p = 0.43). CONCLUSIONS: Administration of silymarin did not cause significant changes in liver iron concentration. Evaluating a longer course of treatment with this drug is thus suggested.
Related Docs
View other Related Docs
1. Combined Therapy of Silymarin and Desferrioxamine in Patients With Β-Thalassemia Major: A Randomized Double-Blind Clinical Trial, Fundamental and Clinical Pharmacology (2009)
2. A Randomized Double-Blind, Placebo-Controlled Study of Therapeutic Effects of Silymarin in Β-Thalassemia Major Patients Receiving Desferrioxamine, European Journal of Haematology (2013)
3. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)
4. Immunomodulatory Effects of Silymarin in Patients With Β-Thalassemia Major, International Immunopharmacology (2013)
5. Comparison of Iron Chelation Effects of Deferoxamine, Deferasirox, and Combination of Deferoxamine and Deferiprone on Liver and Cardiac T2* Mri in Thalassemia Maior, Caspian Journal of Internal Medicine (2017)
6. The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in Β-Thalassemia Patients, Iranian Journal of Pediatric Hematology and Oncology (2019)
7. Protective Role of Silymarin and Deferoxamine Against Iron Dextran-Induced Renal Iron Deposition in Male Rats, International Journal of Preventive Medicine (2013)
8. Double-Faced Cell-Mediated Immunity in Β-Thalassemia Major: Stimulated Phenotype Versus Suppressed Activity, Annals of Hematology (2009)
Experts (# of related papers)
View all Related Experts
Nafiseh Esmaeil (4)
Mohammad Reza Maracy (3)
Other Related Docs
9. Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy, Immunopharmacology and Immunotoxicology (2014)
10. The Correlation Between the Cardiac and Hepatic Iron-Overload in Patients With Thalassemia Major Who Received Multiple Transfusion, Journal of Isfahan Medical School (2010)
11. Efficacy and Safety of Iranian Made Deferasirox (Osveral®)In Iranian Major Thalassemic Patients With Transfusional Iron Overload: A One Year Prospective Multicentric Open-Label Non-Comparative Study, DARU, Journal of Pharmaceutical Sciences (2011)
12. An Evaluation of Sensory Neural Hearing Loss in Thalassaemic Patients Treated With Desferrioxamine and Its Risk Factors, Journal of Research in Medical Sciences (2005)
13. Magnetic Resonance Imaging Signal Reduction May Precede Volume Loss in the Pituitary Gland of Transfusion-Dependent Beta-Thalassemic Patients, Acta Radiologica (2010)
14. T2-Weighted Cardiovascular Magnetic Resonance and Echocardiographic Arterial Elasticity Criteria for Monitoring Cardiac Siderosis in Patients With Beta-Thalassemia Major, Journal of Research in Medical Sciences (2022)
15. Correlation of N-Terminal Pro-B-Type Natriuretic Peptide Levels and Cardiac Magnetic Resonance Imaging T2∗ in Patients With Β-Thalassaemia Major, Blood Transfusion (2016)
16. Inhibition of Apoptosis and Proliferation in T Cells by Immunosuppressive Silymarine, Iranian Journal of Allergy, Asthma and Immunology (2017)
17. Assessment of the Relationship Between Iron Overload Based on Cardiac T2* Mri and Fragmented Qrs in Beta-Thalassemia Major Patients, Shiraz E Medical Journal (2020)
18. Co-Administration of Silymarin and Deferoxamine Against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model, International Journal of Preventive Medicine (2014)
19. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, in Patients With Β-Thalassemia Major, Hemoglobin (2013)
20. Premature Senescence of T Lymphocytes From Patients With Β-Thalassemia Major, Immunology Letters (2009)
21. Chmmotv1 - Cardiac and Hepatic Multi-Echo (T2*) Mri Images and Clinical Dataset for Iron Overload on Thalassemia Patients, BMC Research Notes (2023)
22. Silymarin Impacts on Immune System As an Immunomodulator: One Key for Many Locks, International Immunopharmacology (2017)
23. Effects of Silymarin on the Proliferation and Glutathione Levels of Peripheral Blood Mononuclear Cells From Β-Thalassemia Major Patients, International Immunopharmacology (2006)
24. The Effect of Silymarin on Non-Alcoholic Fatty Liver Disease of Children, Journal of HerbMed Pharmacology (2017)
25. Silymarin Suppress Cd4+ T Cell Activation and Proliferation: Effects on Nf-Κb Activity and Il-2 Production, Pharmacological Research (2010)
26. Effects of Silymarin Supplementation on Blood Lipids: A Systematic Review and Meta-Analysis of Clinical Trials, Phytotherapy Research (2019)
27. Evaluation of Iron Status by Serum Ferritin Level in Iranian Carriers of Beta Thalassemia Minor, International Journal for Vitamin and Nutrition Research (2008)
28. Effects of Silybum Marianum on Patients With Chronic Hepatitis C, Journal of Research in Medical Sciences (2011)
29. The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major, Iranian Journal of Blood and Cancer (2018)
30. The Hepatorenal Protective Effects of Silymarin in Cancer Patients Receiving Chemotherapy: A Randomized, Placebo-Controlled Trial, BMC Complementary Medicine and Therapies (2024)
31. Effect of Livergol on the Improvement of Fatty Liver in Patients With Cancer Undergoing Irinotecan- and Oxaliplatin-Based Chemotherapy Regimen, Journal of Research in Medical Sciences (2018)
32. Correlation Between Myocardial Iron Overload Detected by Cmrt2∗ and Left Ventricular Function Assessed by Tissue Doppler Imaging in Patients With Thalassemia Major, Journal of Cardiovascular Echography (2022)
33. Review on Iron and Its Importance for Human Health, Journal of Research in Medical Sciences (2014)